$SOPH News

SOPHiA GENETICS SA 2026 Q1 - Results - Earnings Call Presentation

BTIG Reiterates Buy on Sophia Genetics, Maintains $8 Price Target

SOPHiA GENETICS S.A. Q1 2026 Earnings Call Summary

SOPHiA Genetics (SOPH) Q1 2026 Earnings Transcript

SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript

BTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8

SOPHiA GENETICS (NASDAQ:SOPH) Q1 Revenue Beats Estimates but Earnings Miss Sparks Pre-Market Decline

SOPHiA GENETICS Reports First Quarter 2026 Results

Sophia Genetics Affirms FY2026 Sales Guidance of $92.000M-$94.000M vs $93.250M Est

Sophia Genetics Q1 EPS $(0.27) Misses $(0.25) Estimate, Sales $21.688M Beat $20.400M Estimate

How The SOPHiA GENETICS (NasdaqGS:SOPH) Narrative Is Shifting With New Fair Value Targets

SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026

Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026

SOPHiA GENETICS Announces Mount Sinai Health System To Implement Its SOPHiA DDM Platform

BTIG Maintains Buy on Sophia Genetics, Raises Price Target to $8

How The SOPHiA GENETICS (SOPH) Narrative Is Shifting With Recalibrated Growth And Valuation Assumptions

Sophia Genetics SA (SOPH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

SOPHiA GENETICS Q4 Earnings Call Highlights

SOPHiA GENETICS S.A. Q4 2025 Earnings Call Summary

SOPHiA GENETICS shares are trading lower after the company reported worse-than-expected Q4 EPS results.